Objective: To estimate infl uenza vaccine coverage and eff ectiveness against medically attended laboratory-confi rmed infl uenza for the 2012 season.
T he Australian Sentinel Practices Research Network (ASPREN) is a network of sentinel general practitioners run through the Royal Australian College of General Practitioners and the University of Adelaide. 1 It has collected de-identifi ed information on infl uenza-like illness and other conditions seen in general practice across Australia since 1991. ASPREN GPs are distributed based on a target of one GP per Division of General Practice, or one GP per 200 000 population for metropolitan areas and one GP per 50 000 population for rural and remote areas. Previous evaluations of ASPREN suggest that it provides timely data on infl uenza-like illness (ILI), and rates consistent with those from other surveillance systems. 2,3 2,3 Since 2009, GPs have collected specimens for infl uenza testing, allowing estimation of infl uenza vaccine effectiveness (VE). We estimated infl uenza vaccine coverage and effectiveness for the 2012 season.
Methods
Data were collected throughout 2012. A total of 275 GPs submitted data to ASPREN, of whom 110 submitted swabs. GPs are instructed to swab, at their discretion, roughly 25% of patients presenting with ILI (fever, cough and fatigue) and forward samples to SA Pathology for testing (see Appendix 1, online at mja.com.au, for laboratory methods). GPs also collect demographic data (age, sex) and the year of most recent infl uenza vaccination. Patients provided written informed consent for a swab sample to be collected and for the results to be used for surveillance purposes. As data were de-identifi ed and obtained in accordance with the National Health Security Act 2007 (Cwlth), human research ethics committee approval was not required.
Differences were compared by odds ratios, the χ 2 test for categorical variables and the t test for continuous variables. All P values were two-sided. VE estimates were made using the testnegative design, 4-6 4-6 where the exposure odds among patients testing positive by reverse transcription real-time polymerase chain reaction for infl uenza are compared with those for patients testing negative. We estimated crude VE as (1 − OR)*100% using logistic regression. Adjusted estimates controlled for age group (< 5, 5-17, 18-49, 50-64 , у 65 years), month of consultation and state or territory (random effect). VE was calculated for the epidemic period in each state or territory. Additionally, VE was estimated excluding patients who were negative for both infl uenza and non-infl uenza pathogens (pannegative), as it has been suggested that this may reduce misascertainment bias due to false-negative infl uenza tests. 7 All analyses were conducted in Stata version 12 (StataCorp).
Results

ASPREN GPs reported consultations
for 5195 patients with ILI, of whom 1775 (34%) were swabbed. The earliest infl uenza cases were identifi ed in New South Wales and Queensland, while Tasmania was the last to report a case (Appendix 2, online at mja.com.au). Three-hundred and sixty-one samples were excluded: one was missing laboratory results; 121 were missing patient vaccination information; and four were missing the patient's date of birth. Patients without vaccination information were younger by 3.7 years (P = 0.04) but had a similar sex distribution to other patients (P = 0.4). Data were plotted to identify the epidemic period (Weeks 10-43 of 2012, see Appendix 2), excluding a further 235 patients. The fi nal sample for VE estimates consisted of 1414 patients, including 593 (42%) who were infl uenza test-positive (Box 1).
Demographic and clinical characteristics are shown in Box 2. Vaccination coverage among test-negative patients was 27%. Coverage was highest among those aged у 65 years (84%), 37% among patients aged 50-64 years, 18% among patients aged 18-49 years, 8% among patients aged 5-17 years and lowest among those aged under 5 years, at 3%. Antigenic characterisation was performed for 41 A(not H1) viruses, all of which were A(H3); 33 of these were A/Perth/16/2009-like viruses, the strain included in the 2010-2012 vaccines (Box 2). Closer examination indicated that four (50%) of the low-reacting viruses were obtained from vaccinated patients.
Crude and adjusted VE estimates are shown in Box 3. The overall crude VE was 33% (95% CI, 13% to 48%), which decreased to 23% (95% CI, − 4% to 43%) after adjusting for age group, month and state or territory. Adjusted VE estimates were higher for infl uenza B (53%; 95% CI, 5% to 77%) and lower for infl uenza A(not H1) (13%; 95% CI, − 20% to 36%). Age-stratifi ed estimates indicated higher VE among older patients (67%; 95% CI, 23% to 86%), and point estimates of 12% for children (< 18 years) and working-age adults (18-64 years). Estimates changed little when pan-negative patients were excluded (Box 3). HI result § (n = 74) (n = 8) (n = 32) (n = 3) (n = 16) (n = 7) (n = 3) (n = 5) 
Discussion
Our study showed low overall adjusted VE of 23% for the 2012 season. However, point estimates were higher against infl uenza B (53%) and lower against infl uenza A(not H1) (13%). If we assume, based on antigenic data, that the majority of A(not H1) viruses were A(H3), then it is unsurprising that this estimate was so low. For example, the 2011-12 estimate for A(H3) reported from Europe was 25% (95% CI, − 6% to 47% 8 ), and the United Kingdom estimate was 23% (95% CI, − 10% to 47% 9 ). Suboptimal VE against A(H3) has been partially attributed to poor match of the circulating strains to the vaccine. 10-12 10-12 Indeed, the limited antigenic data available suggested four out of 10 vaccinated patients had viruses antigenically dissimilar to the vaccine strain. Moreover, the vaccine component for A(H3) was updated for the 2013 southern hemisphere season. 13 13 A somewhat surprising fi nding of this study was the strong protective effect of the vaccine among older people. During the 2011-12 European season, VE for people у 60 years was 15% (95% CI, − 33% to 46%), while for workingage adults (15-59 years) it was 63% (95% CI, 26% to 82%). 8 This is in direct contrast with the estimates reported here of 12% (95% CI, − 22% to 36%) for working-age adults and 67% (95% CI, 23% to 86%) for older people. In Spain, VE has been observed to be high (85%; 95% CI, − 8% to 98%) for older patients presenting within 100 days of vaccination. 14 14 Our data did not indicate earlier presentation after vaccination by older patients compared with younger patients and did not allow us to stratify by time since vaccination. In addition, we did not collect data on the presence of conditions predisposing to severe infl uenza, such as asthma, obesity and immunocompromising conditions. Failure to adjust for this important confounder 15 15 may have accounted for the unexpected age effects.
Our study was limited by incomplete vaccination data on a number of patients. We were unable to exclude patients on the basis of presenting too soon after vaccination or too late after symptom onset, 4,16,17 4,16,17 which may contribute to misclassifi cation bias.
To overcome these limitations in future seasons, we have revised the data collection procedures for ASPREN GPs.
